Jumjum Pharma Q2 profit hits 137.6M

Jamjoom Pharma achieved a net profit of 137.63 million SAR in the second quarter of 2026, representing a year-over-year increase of 4.25%. Revenues rose by 12.4% to reach 445.31 million SAR, driven by higher sales volumes, successful product distribution, and sustained demand for strategic products, especially in the Gulf and North African markets. However, profits declined by 18.18% compared to the first quarter of the same year due to rising expenses and negative movements in other income and income from joint ventures. For the first half of 2026, net profit increased to 305.84 million SAR, up 5.81%, supported by an 8.54% rise in revenues, reflecting increased sales and expansion in key markets. Additionally, shareholders' equity grew by 11.68% to reach 1.88 billion SAR, and earnings per share increased to 4.37 SAR.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل